Amir Tabatabai, MD
Hematology/Oncology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 7
- 3 carriers
- Offices
- 2
Offices
2 locations · Monterey Bay Oncology A Medical Corporation · Dignity Health Medical Foundation
Hospitals listed: Dominican Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
7 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tabatabai’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
7 of 7 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$665,709
Medicare paid this office $665,709 for 503 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11 | $75,718 | None |
| Injection, denosumab, 1 mg | 15 | $44,664 | None |
| Long return visit (40+ min) | 124 | $29,070 | $132 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 13 | $16,086 | $96 |
| Return visit (30+ min) | 138 | $13,332 | $84 |
See all 35 services
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11 | $75,718 | None |
| Injection, denosumab, 1 mg | 15 | $44,664 | None |
| Long return visit (40+ min) | 124 | $29,070 | $132 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 13 | $16,086 | $96 |
| Return visit (30+ min) | 138 | $13,332 | $84 |
| New patient visit (60+ min) | 73 | $13,029 | $178 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $8,372 | None |
| Short return visit (20+ min) | 103 | $7,415 | $66 |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $5,989 | $92 |
| Insertion of needle into vein for collection of blood sample | 123 | $2,232 | $9 |
| Blood test, comprehensive group of blood chemicals | 96 | $2,039 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 116 | $1,843 | $8 |
| New patient visit (45+ min) | 14 | $1,671 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 35 | $1,587 | $21 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $1,429 | $79 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $1,286 | $46 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $982 | $47 |
| Injection of drug or substance under skin or into muscle | 57 | $899 | $11 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 18 | $772 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $650 | $43 |
| Blood test, thyroid stimulating hormone (tsh) | 22 | $527 | $16 |
| Injection of additional new drug or substance into vein | 25 | $490 | $11 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $436 | $27 |
| Administration of chemotherapy into vein, each additional hour | 16 | $423 | $20 |
| Psa (prostate specific antigen) measurement, total | 12 | $414 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $268 | $15 |
| Ferritin (blood protein) level | 18 | $267 | $13 |
| Injection, palonosetron hcl, 25 mcg | 22 | $166 | None |
| Lactate dehydrogenase (enzyme) level | 16 | $160 | $6 |
| Iron binding capacity | 15 | $154 | $9 |
| Magnesium level | 14 | $145 | $7 |
| Iron level | 16 | $120 | $6 |
| Injection, granisetron hydrochloride, 100 mcg | 13 | $54 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 25 | $34 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $9 | None |
Who their Medicare patients are
503 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 56% · Also on Medicaid 13% · Health risk score 2.36. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 50% · Chronic kidney disease 36% · Coronary heart disease 32% · Diabetes 28% · Depression 27% · Atrial fibrillation 25% · Heart failure 21% · COPD 17% · Stroke 8% · Dementia 6%.
The office billed $1,594,502, Medicare allowed $848,795 and paid $665,709; for 31,663 services of 126 kinds; $572,572 of it was for drugs given in the office and $93,137 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 503 | 31,663 | 75 | 2.36 | $1,594,502 | $665,709 |
| 2023 | 711 | 136,676 | 75 | 2.55 | $5,384,490 | $2,629,350 |
| 2022 | 840 | 180,184 | 75 | 2.30 | $6,730,816 | $3,309,335 |
| 2021 | 897 | 134,277 | 74 | 2.36 | $5,385,821 | $2,836,408 |
| 2020 | 760 | 144,087 | 74 | 2.47 | $4,206,907 | $2,148,463 |
| 2019 | 895 | 180,334 | 74 | 2.42 | $4,998,992 | $2,530,484 |
| 2018 | 822 | 149,557 | 74 | 2.25 | $4,247,229 | $2,148,539 |
| 2017 | 898 | 179,536 | 74 | 2.12 | $4,449,426 | $2,204,979 |
| 2016 | 814 | 189,044 | 74 | 2.29 | $4,675,225 | $2,249,241 |
| 2015 | 859 | 189,776 | 74 | 2.11 | $4,878,892 | $2,193,490 |
| 2014 | 860 | 186,450 | 74 | 2.09 | $5,029,059 | $2,225,241 |
| 2013 | 753 | 170,236 | 74 | 1.98 | $4,420,172 | $1,934,156 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 64 services
| Injection, pembrolizumab, 1 mg | 28 | $483,500 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 22 | $303,474 | None |
| Injection, nivolumab, 1 mg | 13 | $176,998 | None |
| Injection, denosumab, 1 mg | 43 | $112,306 | None |
| Long return visit (40+ min) | 186 | $58,970 | $130 |
| Injection, ferric derisomaltose, 10 mg | 27 | $47,387 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 43 | $45,745 | None |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 26 | $45,421 | $102 |
| Administration of chemotherapy into vein, 1 hour or less | 169 | $28,925 | $98 |
| Return visit (30+ min) | 158 | $20,518 | $88 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 17 | $15,797 | $73 |
| Injection, bortezomib, 0.1 mg | 15 | $10,485 | None |
| Insertion of needle into vein for collection of blood sample | 246 | $9,091 | $8 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $8,543 | $136 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 245 | $8,439 | $8 |
| Blood test, comprehensive group of blood chemicals | 169 | $8,017 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 114 | $7,521 | $21 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 40 | $7,036 | $54 |
| Short return visit (20+ min) | 93 | $6,087 | $56 |
| New patient visit (60+ min) | 31 | $5,222 | $168 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 19 | $4,851 | $128 |
| Injection, fulvestrant, 25 mg | 15 | $4,592 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 55 | $4,189 | $49 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 55 | $3,010 | $46 |
| Administration of chemotherapy into vein, each additional hour | 57 | $2,971 | $21 |
| Injection of drug or substance under skin or into muscle | 145 | $2,737 | $11 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $2,512 | $93 |
| Injection of additional new drug or substance into vein | 77 | $2,074 | $11 |
| Injection, azacitidine, 1 mg | 11 | $2,001 | None |
| Blood test, thyroid stimulating hormone (tsh) | 36 | $1,778 | $16 |
| Administration of additional new drug or substance into vein using push technique | 25 | $1,536 | $40 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 11 | $1,407 | $20 |
| Psa (prostate specific antigen) measurement, total | 18 | $1,153 | $18 |
| Injection, leucovorin calcium, per 50 mg | 14 | $1,140 | None |
| Carcinoembryonic antigen (cea) protein level | 21 | $1,040 | $19 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $1,033 | $26 |
| Injection, palonosetron hcl, 25 mcg | 74 | $1,009 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 23 | $990 | $15 |
| Infusion into a vein for hydration, 31-60 minutes | 22 | $942 | $25 |
| Ferritin (blood protein) level | 38 | $828 | $13 |
| Magnesium level | 36 | $756 | $7 |
| Infusion into a vein for hydration, each additional hour | 29 | $721 | $10 |
| Injection, fosaprepitant, 1 mg | 27 | $685 | None |
| Injection, fluorouracil, 500 mg | 19 | $631 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 33 | $621 | $17 |
| Injection, zoledronic acid, 1 mg | 17 | $544 | None |
| Injection, irinotecan, 20 mg | 12 | $531 | None |
| Iron binding capacity | 34 | $497 | $9 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 19 | $462 | None |
| Injection, oxaliplatin, 0.5 mg | 12 | $391 | None |
| Lactate dehydrogenase (enzyme) level | 34 | $379 | $6 |
| Iron level | 34 | $368 | $6 |
| Injection, paclitaxel, 1 mg | 15 | $353 | None |
| Irrigation of implanted venous access drug delivery device | 18 | $347 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $334 | $15 |
| Injection, carboplatin, 50 mg | 18 | $324 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 94 | $199 | None |
| Injection, granisetron hydrochloride, 100 mcg | 30 | $110 | None |
| Injection, atropine sulfate, 0.01 mg | 16 | $93 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 53 | $67 | None |
| Blood creatinine level | 11 | $55 | $5 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $51 | None |
| Infusion, normal saline solution , 1000 cc | 11 | $33 | None |
| Unclassified drugs | 30 | $27 | None |
2022: 76 services
| Injection, pembrolizumab, 1 mg | 28 | $649,407 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 25 | $314,501 | None |
| Injection, nivolumab, 1 mg | 19 | $304,992 | None |
| Injection, denosumab, 1 mg | 53 | $124,499 | None |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 40 | $102,315 | $133 |
| Injection, bortezomib, 0.1 mg | 23 | $102,050 | None |
| Injection, paclitaxel protein-bound particles, 1 mg | 13 | $93,300 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 54 | $85,599 | None |
| Long return visit (40+ min) | 251 | $81,629 | $132 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 19 | $66,217 | $36 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 19 | $59,453 | $36 |
| Injection, ferric derisomaltose, 10 mg | 25 | $50,628 | None |
| Administration of chemotherapy into vein, 1 hour or less | 201 | $45,123 | $105 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 11 | $35,053 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 65 | $31,299 | $160 |
| Return visit (30+ min) | 186 | $23,192 | $88 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 142 | $12,459 | $23 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 67 | $10,700 | $155 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 61 | $10,464 | $56 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 362 | $9,814 | $8 |
| New patient visit (60+ min) | 60 | $9,595 | $160 |
| Blood test, comprehensive group of blood chemicals | 229 | $9,113 | $10 |
| Short return visit (20+ min) | 123 | $8,825 | $62 |
| Cyclophosphamide, 100 mg | 17 | $7,672 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 61 | $6,975 | $51 |
| Injection, fulvestrant, 25 mg | 15 | $6,025 | None |
| Injection, azacitidine, 1 mg | 14 | $5,599 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $5,059 | $80 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $4,923 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 66 | $4,191 | $49 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 21 | $3,836 | $128 |
| Insertion of needle into vein for collection of blood sample | 317 | $3,503 | $3 |
| Injection of drug or substance under skin or into muscle | 170 | $3,445 | $11 |
| Blood test, thyroid stimulating hormone (tsh) | 49 | $2,454 | $17 |
| Administration of additional new drug or substance into vein using push technique | 31 | $2,448 | $45 |
| Injection of additional new drug or substance into vein | 92 | $2,410 | $12 |
| Administration of chemotherapy into vein, each additional hour | 50 | $2,307 | $23 |
| Administration of chemotherapy into vein using push technique | 18 | $2,276 | $81 |
| Infusion into a vein for hydration, 31-60 minutes | 54 | $2,127 | $26 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 14 | $1,912 | $21 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,843 | $56 |
| Infusion into a vein for hydration, each additional hour | 59 | $1,695 | $10 |
| Psa (prostate specific antigen) measurement, total | 17 | $1,380 | $18 |
| Ferritin (blood protein) level | 66 | $1,318 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $1,235 | $24 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 21 | $1,232 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 55 | $1,114 | $17 |
| Injection, palonosetron hcl, 25 mcg | 86 | $1,106 | None |
| Magnesium level | 57 | $866 | $7 |
| Injection, fosaprepitant, 1 mg | 26 | $852 | None |
| Injection, zoledronic acid, 1 mg | 23 | $791 | None |
| Injection, leucovorin calcium, per 50 mg | 23 | $783 | None |
| Carcinoembryonic antigen (cea) protein level | 14 | $769 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $752 | $16 |
| Lactate dehydrogenase (enzyme) level | 63 | $608 | $6 |
| Iron binding capacity | 45 | $587 | $9 |
| Injection, fluorouracil, 500 mg | 26 | $527 | None |
| Irrigation of implanted venous access drug delivery device | 23 | $452 | $17 |
| Iron level | 45 | $434 | $6 |
| Injection, carboplatin, 50 mg | 19 | $412 | None |
| Injection, granisetron hydrochloride, 100 mcg | 44 | $345 | None |
| Injection, oxaliplatin, 0.5 mg | 14 | $336 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $302 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 116 | $285 | None |
| Blood test, basic group of blood chemicals (calcium, total) | 28 | $283 | $8 |
| Injection, paclitaxel, 1 mg | 12 | $276 | None |
| Infusion, normal saline solution , 1000 cc | 50 | $239 | None |
| Calcium level, total | 15 | $97 | $5 |
| Injection, diphenhydramine hcl, up to 50 mg | 66 | $93 | None |
| Uric acid level, blood | 15 | $89 | $4 |
| Blood creatinine level | 16 | $86 | $5 |
| Phosphate level | 12 | $75 | $5 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $44 | None |
| Injection, atropine sulfate, 0.01 mg | 12 | $38 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $33 | None |
| Unclassified drugs | 33 | $28 | None |
2021: 79 services
| Injection, pembrolizumab, 1 mg | 23 | $363,286 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 20 | $264,024 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 164 | $150,796 | $161 |
| Injection, nivolumab, 1 mg | 11 | $142,230 | None |
| Injection, denosumab, 1 mg | 57 | $112,154 | None |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 36 | $109,974 | $183 |
| Injection, bortezomib, 0.1 mg | 23 | $102,064 | None |
| Long return visit (40+ min) | 296 | $80,357 | $136 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 14 | $73,689 | $50 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 18 | $66,548 | $44 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 47 | $63,126 | None |
| Injection, ferric derisomaltose, 10 mg | 26 | $54,755 | None |
| Administration of chemotherapy into vein, 1 hour or less | 178 | $40,349 | $112 |
| Return visit (30+ min) | 183 | $23,746 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $15,564 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 157 | $13,959 | $25 |
| New patient visit (60+ min) | 86 | $13,951 | $162 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 71 | $11,258 | $62 |
| Injection, fulvestrant, 25 mg | 11 | $10,906 | None |
| Short return visit (20+ min) | 127 | $9,599 | $64 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 381 | $9,184 | $8 |
| Blood test, comprehensive group of blood chemicals | 240 | $8,026 | $11 |
| Injection, azacitidine, 1 mg | 14 | $7,642 | None |
| Cyclophosphamide, 100 mg | 14 | $7,054 | None |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 20 | $4,915 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $4,751 | $82 |
| Administration of additional new drug or substance into vein, 1 hour or less | 58 | $4,680 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 68 | $4,547 | $55 |
| Insertion of needle into vein for collection of blood sample | 343 | $3,321 | $3 |
| Administration of additional new drug or substance into vein using push technique | 36 | $3,094 | $48 |
| Injection of additional new drug or substance into vein | 88 | $2,372 | $13 |
| Injection of drug or substance under skin or into muscle | 137 | $2,365 | $11 |
| Administration of chemotherapy into vein using push technique | 14 | $2,341 | $87 |
| Injection, palonosetron hcl, 25 mcg | 84 | $2,316 | None |
| Administration of chemotherapy into vein, each additional hour | 34 | $2,083 | $24 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 85 | $1,998 | $18 |
| Blood test, thyroid stimulating hormone (tsh) | 38 | $1,831 | $17 |
| Infusion into a vein for hydration, 31-60 minutes | 47 | $1,786 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $1,767 | $57 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 16 | $1,561 | $21 |
| Injection, fosaprepitant, 1 mg | 29 | $1,488 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $1,350 | $17 |
| Ferritin (blood protein) level | 62 | $1,349 | $14 |
| Infusion into a vein for hydration, each additional hour | 45 | $1,142 | $10 |
| Injection, zoledronic acid, 1 mg | 26 | $1,107 | None |
| Carcinoembryonic antigen (cea) protein level | 16 | $948 | $19 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 22 | $943 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $843 | $24 |
| Magnesium level | 63 | $791 | $7 |
| Psa (prostate specific antigen) measurement, total | 13 | $754 | $18 |
| Injection, docetaxel, 1 mg | 11 | $748 | None |
| Injection, leucovorin calcium, per 50 mg | 18 | $732 | None |
| Lactate dehydrogenase (enzyme) level | 49 | $664 | $6 |
| Injection, oxaliplatin, 0.5 mg | 14 | $626 | None |
| Iron binding capacity | 44 | $568 | $9 |
| Injection, irinotecan, 20 mg | 11 | $509 | None |
| Injection, fluorouracil, 500 mg | 23 | $480 | None |
| Iron level | 45 | $433 | $6 |
| Telephone medical discussion with physician, 5-10 minutes | 14 | $400 | $27 |
| Irrigation of implanted venous access drug delivery device | 19 | $398 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $379 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 120 | $355 | None |
| Injection, carboplatin, 50 mg | 19 | $345 | None |
| Blood test, basic group of blood chemicals (calcium, total) | 32 | $313 | $8 |
| Injection, cisplatin, powder or solution, 10 mg | 15 | $245 | None |
| Injection, granisetron hydrochloride, 100 mcg | 45 | $242 | None |
| Infusion, normal saline solution , 1000 cc | 50 | $193 | None |
| Uric acid level, blood | 21 | $176 | $5 |
| Urinalysis, manual test | 11 | $108 | $3 |
| Phosphate level | 14 | $85 | $5 |
| Injection, diphenhydramine hcl, up to 50 mg | 81 | $80 | None |
| Blood creatinine level | 15 | $77 | $5 |
| Injection, magnesium sulfate, per 500 mg | 16 | $73 | None |
| Calcium level, total | 11 | $67 | $5 |
| Injection, atropine sulfate, 0.01 mg | 11 | $58 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 22 | $45 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 18 | $38 | None |
| Unclassified drugs | 45 | $38 | None |
| Injection, mannitol, 25% in 50 ml | 11 | $23 | None |
2020: 71 services
| Injection, pembrolizumab, 1 mg | 20 | $226,815 | None |
| Injection, nivolumab, 1 mg | 12 | $142,383 | None |
| Injection, denosumab, 1 mg | 58 | $111,758 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 119 | $105,974 | $159 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 25 | $91,433 | $231 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 43 | $83,503 | None |
| Injection, bortezomib, 0.1 mg | 18 | $78,519 | None |
| Unclassified biologics | 13 | $65,880 | None |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 13 | $63,451 | $51 |
| Long return visit (40+ min) | 242 | $58,929 | $110 |
| Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 11 | $49,584 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 175 | $34,338 | $105 |
| Injection, ferric carboxymaltose, 1 mg | 26 | $18,494 | None |
| Return visit (30+ min) | 124 | $12,824 | $77 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 140 | $10,884 | $24 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $9,463 | $163 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 361 | $7,976 | $8 |
| New patient visit (60+ min) | 47 | $7,272 | $155 |
| Short return visit (20+ min) | 119 | $7,201 | $48 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 62 | $7,159 | $58 |
| Blood test, comprehensive group of blood chemicals | 214 | $6,822 | $10 |
| Injection, azacitidine, 1 mg | 13 | $6,501 | None |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 27 | $6,225 | $124 |
| Administration of additional new drug or substance into vein, 1 hour or less | 53 | $4,550 | $53 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 63 | $3,914 | $51 |
| Injection, fosaprepitant, 1 mg | 19 | $3,903 | None |
| Injection, palonosetron hcl, 25 mcg | 62 | $3,315 | None |
| Insertion of needle into vein for collection of blood sample | 346 | $3,040 | $3 |
| Administration of additional new drug or substance into vein using push technique | 32 | $2,701 | $46 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $2,699 | $84 |
| Administration of chemotherapy into vein, each additional hour | 49 | $2,614 | $23 |
| Injection of drug or substance under skin or into muscle | 118 | $2,189 | $10 |
| Infusion into a vein for hydration, 31-60 minutes | 51 | $2,169 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $1,981 | $58 |
| Injection of additional new drug or substance into vein | 69 | $1,875 | $13 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 63 | $1,539 | $17 |
| Infusion into a vein for hydration, each additional hour | 56 | $1,465 | $11 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 11 | $1,386 | $21 |
| Blood test, thyroid stimulating hormone (tsh) | 33 | $1,270 | $16 |
| Ferritin (blood protein) level | 56 | $1,083 | $13 |
| Injection, oxaliplatin, 0.5 mg | 15 | $941 | None |
| Psa (prostate specific antigen) measurement, total | 13 | $765 | $18 |
| Injection, irinotecan, 20 mg | 14 | $692 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $691 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $665 | $17 |
| Magnesium level | 42 | $641 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 22 | $641 | $16 |
| Injection, fluorouracil, 500 mg | 28 | $622 | None |
| Irrigation of implanted venous access drug delivery device | 22 | $620 | $21 |
| Lactate dehydrogenase (enzyme) level | 57 | $558 | $6 |
| Iron binding capacity | 43 | $520 | $9 |
| Injection, leucovorin calcium, per 50 mg | 25 | $505 | None |
| Blood test, basic group of blood chemicals (calcium, total) | 42 | $445 | $8 |
| Carcinoembryonic antigen (cea) protein level | 12 | $396 | $19 |
| Iron level | 43 | $392 | $6 |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $342 | $28 |
| Injection, carboplatin, 50 mg | 15 | $335 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 109 | $256 | None |
| Infusion, normal saline solution , 1000 cc | 49 | $194 | None |
| Injection, granisetron hydrochloride, 100 mcg | 39 | $183 | None |
| Injection, etoposide, 10 mg | 11 | $170 | None |
| Uric acid level, blood | 19 | $144 | $4 |
| Phosphate level | 13 | $89 | $4 |
| Urinalysis, manual test | 15 | $69 | $3 |
| Calcium level, total | 13 | $66 | $5 |
| Injection, diphenhydramine hcl, up to 50 mg | 66 | $59 | None |
| Injection, atropine sulfate, 0.01 mg | 14 | $57 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $48 | None |
| Unclassified drugs | 36 | $35 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $27 | None |
| Injection, furosemide, up to 20 mg | 11 | $7 | None |
2019: 69 services
| Injection, pembrolizumab, 1 mg | 29 | $278,134 | None |
| Injection, nivolumab, 1 mg | 21 | $246,860 | None |
| Injection, denosumab, 1 mg | 87 | $230,268 | None |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 43 | $174,331 | $269 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 140 | $125,597 | $157 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 60 | $112,195 | None |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 13 | $78,405 | None |
| Injection, rituximab, 10 mg | 14 | $73,204 | None |
| Injection, bortezomib, 0.1 mg | 21 | $67,586 | None |
| Long return visit (40+ min) | 235 | $50,207 | $107 |
| Administration of chemotherapy into vein, 1 hour or less | 193 | $35,659 | $106 |
| Injection, ferric carboxymaltose, 1 mg | 39 | $29,421 | None |
| Return visit (30+ min) | 140 | $15,260 | $78 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 92 | $12,543 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $11,303 | $161 |
| Short return visit (20+ min) | 164 | $11,094 | $53 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 148 | $10,996 | $24 |
| Injection, azacitidine, 1 mg | 16 | $10,320 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 472 | $8,807 | $8 |
| New patient visit (60+ min) | 55 | $8,478 | $154 |
| Injection, palonosetron hcl, 25 mcg | 62 | $7,656 | None |
| Blood test, comprehensive group of blood chemicals | 293 | $7,194 | $11 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 76 | $4,552 | $52 |
| Injection, fosaprepitant, 1 mg | 16 | $4,178 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 58 | $3,917 | $52 |
| Injection of drug or substance under skin or into muscle | 154 | $3,443 | $12 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 16 | $3,204 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,072 | $83 |
| Administration of chemotherapy into vein using push technique | 11 | $3,064 | $83 |
| Insertion of needle into vein for collection of blood sample | 486 | $2,981 | $3 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $2,787 | $58 |
| Administration of chemotherapy into vein, each additional hour | 51 | $2,735 | $24 |
| Infusion into a vein for hydration, 31-60 minutes | 56 | $2,538 | $29 |
| Administration of additional new drug or substance into vein using push technique | 26 | $2,156 | $45 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 74 | $1,654 | $17 |
| Injection of additional new drug or substance into vein | 65 | $1,481 | $13 |
| Blood test, thyroid stimulating hormone (tsh) | 40 | $1,427 | $18 |
| Infusion into a vein for hydration, each additional hour | 51 | $1,148 | $10 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 20 | $1,126 | None |
| Psa (prostate specific antigen) measurement, total | 19 | $1,062 | $20 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 19 | $907 | $23 |
| Ferritin (blood protein) level | 39 | $906 | $15 |
| Carcinoembryonic antigen (cea) protein level | 26 | $743 | $21 |
| Injection, leucovorin calcium, per 50 mg | 13 | $646 | None |
| Injection, zoledronic acid, 1 mg | 15 | $621 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $572 | $24 |
| Magnesium level | 54 | $532 | $7 |
| Irrigation of implanted venous access drug delivery device | 21 | $485 | $19 |
| Injection, oxaliplatin, 0.5 mg | 11 | $482 | None |
| Injection, carboplatin, 50 mg | 22 | $468 | None |
| Lactate dehydrogenase (enzyme) level | 54 | $467 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 16 | $403 | $16 |
| Injection, granisetron hydrochloride, 100 mcg | 44 | $336 | None |
| Iron binding capacity | 27 | $333 | $10 |
| Injection, fluorouracil, 500 mg | 16 | $265 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $260 | $16 |
| Blood test, basic group of blood chemicals (calcium, total) | 27 | $258 | $9 |
| Iron level | 27 | $247 | $7 |
| Injection, paclitaxel, 1 mg | 12 | $243 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 111 | $226 | None |
| Uric acid level, blood | 26 | $177 | $5 |
| Infusion, normal saline solution , 1000 cc | 45 | $154 | None |
| Calcium level, total | 23 | $146 | $6 |
| Blood creatinine level | 15 | $89 | $6 |
| Phosphate level | 13 | $88 | $5 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 28 | $57 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 59 | $39 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 22 | $36 | None |
| Unclassified drugs | 48 | $33 | None |
2018: 72 services
| Injection, nivolumab, 1 mg | 18 | $280,994 | None |
| Injection, denosumab, 1 mg | 63 | $203,386 | None |
| Injection, pembrolizumab, 1 mg | 18 | $190,425 | None |
| Injection, pegfilgrastim, 6 mg | 26 | $133,031 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 137 | $118,854 | $157 |
| Injection, rituximab, 100 mg | 17 | $109,389 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 45 | $98,364 | None |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 12 | $80,513 | None |
| Injection, bortezomib, 0.1 mg | 13 | $54,934 | None |
| Long return visit (40+ min) | 229 | $45,426 | $107 |
| Administration of chemotherapy into vein, 1 hour or less | 185 | $39,788 | $104 |
| Return visit (30+ min) | 156 | $18,509 | $77 |
| Injection, palonosetron hcl, 25 mcg | 70 | $16,868 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $14,187 | $159 |
| Injection, azacitidine, 1 mg | 16 | $12,317 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 471 | $9,740 | $9 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 64 | $9,465 | $60 |
| Short return visit (20+ min) | 130 | $8,830 | $49 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 150 | $8,297 | $24 |
| Blood test, comprehensive group of blood chemicals | 334 | $8,243 | $13 |
| Cyclophosphamide, 100 mg | 14 | $8,063 | None |
| New patient visit (60+ min) | 45 | $7,248 | $161 |
| Injection, fosaprepitant, 1 mg | 23 | $6,681 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 14 | $6,122 | $1 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $4,998 | $82 |
| Injection of additional new drug or substance into vein | 107 | $3,721 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 53 | $3,491 | $52 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 19 | $3,369 | $120 |
| Administration of additional new drug or substance into vein, 1 hour or less | 43 | $3,089 | $51 |
| Injection of drug or substance under skin or into muscle | 101 | $3,038 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $3,032 | $57 |
| Insertion of needle into vein for collection of blood sample | 479 | $2,943 | $3 |
| Administration of chemotherapy into vein, each additional hour | 53 | $2,909 | $24 |
| Administration of chemotherapy into vein using push technique | 14 | $2,806 | $83 |
| Administration of additional new drug or substance into vein using push technique | 30 | $2,215 | $44 |
| Infusion into a vein for hydration, 31-60 minutes | 41 | $2,169 | $34 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 85 | $2,129 | $16 |
| Blood test, thyroid stimulating hormone (tsh) | 47 | $2,033 | $20 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 22 | $1,530 | None |
| Psa (prostate specific antigen) measurement, total | 26 | $1,247 | $22 |
| Infusion into a vein for hydration, each additional hour | 45 | $1,039 | $10 |
| Injection, oxaliplatin, 0.5 mg | 16 | $968 | None |
| Ferritin (blood protein) level | 42 | $874 | $16 |
| Injection, leucovorin calcium, per 50 mg | 18 | $842 | None |
| Carcinoembryonic antigen (cea) protein level | 27 | $803 | $23 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 19 | $731 | $25 |
| Injection, zoledronic acid, 1 mg | 11 | $672 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $584 | $22 |
| Lactate dehydrogenase (enzyme) level | 51 | $540 | $7 |
| Application of on-body injector for under skin injection | 23 | $532 | $16 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $432 | $31 |
| Injection, carboplatin, 50 mg | 16 | $415 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $385 | $17 |
| Unclassified drugs | 31 | $378 | None |
| Short return visit | 11 | $371 | $31 |
| Magnesium level | 35 | $365 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 18 | $350 | $16 |
| Irrigation of implanted venous access drug delivery device | 17 | $317 | $18 |
| Injection, granisetron hydrochloride, 100 mcg | 55 | $292 | None |
| Injection, paclitaxel, 1 mg | 12 | $281 | None |
| Iron binding capacity | 22 | $264 | $11 |
| Injection, doxorubicin hydrochloride, 10 mg | 12 | $238 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 111 | $226 | None |
| Iron level | 22 | $196 | $8 |
| Blood test, basic group of blood chemicals (calcium, total) | 14 | $194 | $10 |
| Infusion, normal saline solution , 1000 cc | 43 | $129 | None |
| Calcium level, total | 17 | $125 | $6 |
| Blood creatinine level | 17 | $112 | $6 |
| Uric acid level, blood | 12 | $88 | $5 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $51 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 69 | $44 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $23 | None |
2017: 66 services
| Injection, pegfilgrastim, 6 mg | 59 | $298,102 | None |
| Injection, nivolumab, 1 mg | 20 | $253,153 | None |
| Injection, denosumab, 1 mg | 80 | $233,887 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 62 | $142,316 | None |
| Injection, bortezomib, 0.1 mg | 21 | $109,175 | None |
| Injection, rituximab, 100 mg | 17 | $100,443 | None |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 11 | $97,851 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 111 | $91,101 | $157 |
| Long return visit (40+ min) | 239 | $56,148 | $105 |
| Injection, fulvestrant, 25 mg | 11 | $37,725 | None |
| Administration of chemotherapy into vein, 1 hour or less | 157 | $35,531 | $101 |
| Injection, ferric carboxymaltose, 1 mg | 33 | $26,247 | None |
| Return visit (30+ min) | 154 | $18,283 | $75 |
| Injection, azacitidine, 1 mg | 13 | $16,434 | None |
| Injection, palonosetron hcl, 25 mcg | 64 | $16,328 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 554 | $14,986 | $10 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $13,981 | $157 |
| Blood test, comprehensive group of blood chemicals | 401 | $11,563 | $14 |
| Short return visit (20+ min) | 157 | $11,089 | $49 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 81 | $10,865 | $53 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 119 | $9,827 | $23 |
| New patient visit (60+ min) | 54 | $8,329 | $154 |
| Cyclophosphamide, 100 mg | 13 | $7,277 | None |
| Injection of drug or substance under skin or into muscle | 167 | $6,833 | $18 |
| Injection, fosaprepitant, 1 mg | 23 | $6,615 | None |
| Infusion into a vein for hydration, 31-60 minutes | 59 | $5,453 | $42 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 60 | $4,564 | $50 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $4,484 | $82 |
| Administration of chemotherapy into vein using push technique | 12 | $4,221 | $83 |
| Insertion of needle into vein for collection of blood sample | 552 | $3,808 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 117 | $2,744 | $14 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 13 | $2,624 | $114 |
| Blood test, thyroid stimulating hormone (tsh) | 49 | $2,575 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $2,390 | $48 |
| Psa (prostate specific antigen) measurement, total | 33 | $2,325 | $25 |
| Administration of chemotherapy into vein, each additional hour | 41 | $2,290 | $21 |
| Injection of additional new drug or substance into vein | 66 | $2,010 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $1,917 | $56 |
| Administration of additional new drug or substance into vein using push technique | 20 | $1,867 | $47 |
| Infusion into a vein for hydration, each additional hour | 59 | $1,814 | $11 |
| Carcinoembryonic antigen (cea) protein level | 44 | $1,810 | $25 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 14 | $1,305 | None |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 22 | $1,203 | $28 |
| Ferritin (blood protein) level | 49 | $1,155 | $18 |
| Injection, zoledronic acid, 1 mg | 16 | $1,023 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $822 | $23 |
| Short return visit | 23 | $765 | $32 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 13 | $755 | $28 |
| Magnesium level | 52 | $667 | $9 |
| Lactate dehydrogenase (enzyme) level | 73 | $534 | $5 |
| Iron binding capacity | 34 | $470 | $12 |
| Injection, carboplatin, 50 mg | 15 | $465 | None |
| Irrigation of implanted venous access drug delivery device | 24 | $385 | $14 |
| Iron level | 34 | $348 | $9 |
| Blood test, basic group of blood chemicals (calcium, total) | 23 | $333 | $11 |
| Injection, granisetron hydrochloride, 100 mcg | 44 | $329 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $327 | $16 |
| Calcium level, total | 30 | $267 | $7 |
| Injection, dexamethasone sodium phosphate, 1 mg | 84 | $188 | None |
| Infusion, normal saline solution , 1000 cc | 54 | $187 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 21 | $77 | None |
| Blood creatinine level | 12 | $75 | $6 |
| Uric acid level, blood | 14 | $74 | $4 |
| Injection, diphenhydramine hcl, up to 50 mg | 58 | $47 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $28 | None |
| Unclassified drugs | 29 | $15 | None |
2016: 64 services
| Injection, pegfilgrastim, 6 mg | 63 | $307,529 | None |
| Injection, denosumab, 1 mg | 72 | $239,857 | None |
| Injection, nivolumab, 1 mg | 18 | $225,946 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 56 | $135,509 | None |
| Injection, bortezomib, 0.1 mg | 19 | $90,819 | None |
| Injection, bevacizumab, 10 mg | 11 | $88,298 | None |
| Injection, rituximab, 100 mg | 12 | $68,261 | None |
| Long return visit (40+ min) | 232 | $60,163 | $104 |
| Injection, azacitidine, 1 mg | 14 | $47,151 | None |
| Administration of chemotherapy into vein, 1 hour or less | 163 | $41,782 | $100 |
| Injection, paclitaxel protein-bound particles, 1 mg | 13 | $27,130 | None |
| Injection, palonosetron hcl, 25 mcg | 76 | $25,697 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 38 | $21,482 | $157 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 16 | $21,390 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 124 | $20,158 | $155 |
| Return visit (30+ min) | 145 | $17,610 | $76 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 268 | $15,601 | $10 |
| Injection, ferric carboxymaltose, 1 mg | 18 | $13,644 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 79 | $12,710 | $55 |
| Blood test, comprehensive group of blood chemicals | 201 | $12,306 | $13 |
| Short return visit (20+ min) | 164 | $10,975 | $49 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 115 | $9,089 | $23 |
| New patient visit (60+ min) | 56 | $8,229 | $147 |
| Injection of drug or substance under skin or into muscle | 153 | $6,699 | $19 |
| Administration of chemotherapy into vein using push technique | 15 | $5,409 | $82 |
| Injection, fosaprepitant, 1 mg | 19 | $5,173 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $3,466 | $81 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 43 | $3,409 | $51 |
| Insertion of needle into vein for collection of blood sample | 256 | $3,299 | $3 |
| Administration of prolonged chemotherapy into vein | 15 | $3,115 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $2,793 | $56 |
| Infusion into a vein for hydration, 31-60 minutes | 38 | $2,718 | $41 |
| Psa (prostate specific antigen) measurement, total | 19 | $2,652 | $25 |
| Administration of chemotherapy into vein, each additional hour | 49 | $2,637 | $21 |
| Injection of additional new drug or substance into vein | 72 | $2,513 | $17 |
| Administration of additional new drug or substance into vein, 1 hour or less | 36 | $2,412 | $46 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 104 | $2,412 | $14 |
| Blood test, thyroid stimulating hormone (tsh) | 24 | $2,355 | $22 |
| Carcinoembryonic antigen (cea) protein level | 21 | $2,329 | $25 |
| Administration of additional new drug or substance into vein using push technique | 23 | $2,213 | $46 |
| Injection, zoledronic acid, 1 mg | 14 | $2,207 | None |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 20 | $2,167 | $28 |
| Injection, oxaliplatin, 0.5 mg | 14 | $2,072 | None |
| Infusion into a vein for hydration, each additional hour | 59 | $2,010 | $11 |
| Irrigation of implanted venous access drug delivery device | 54 | $1,102 | $16 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $905 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $845 | $24 |
| Magnesium level | 34 | $787 | $9 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 21 | $733 | $31 |
| Lactate dehydrogenase (enzyme) level | 55 | $652 | $5 |
| Ferritin (blood protein) level | 22 | $582 | $18 |
| Injection, carboplatin, 50 mg | 17 | $479 | None |
| Injection, granisetron hydrochloride, 100 mcg | 31 | $276 | None |
| Iron binding capacity | 16 | $245 | $12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 82 | $243 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $232 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $213 | $14 |
| Iron level | 16 | $190 | $9 |
| Infusion, normal saline solution , 1000 cc | 35 | $100 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $96 | None |
| Blood creatinine level | 13 | $73 | $5 |
| Injection, diphenhydramine hcl, up to 50 mg | 56 | $37 | None |
| Unclassified drugs | 29 | $23 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $20 | None |
2015: 73 services
| Injection, pegfilgrastim, 6 mg | 79 | $363,942 | None |
| Injection, denosumab, 1 mg | 72 | $202,378 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 61 | $152,381 | None |
| Injection, bevacizumab, 10 mg | 18 | $138,492 | None |
| Injection, rituximab, 100 mg | 19 | $108,099 | None |
| Injection, bortezomib, 0.1 mg | 22 | $104,884 | None |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 14 | $96,545 | None |
| Injection, pemetrexed, not otherwise specified, 10 mg | 12 | $89,872 | None |
| Long return visit (40+ min) | 234 | $60,984 | $107 |
| Injection, paclitaxel protein-bound particles, 1 mg | 15 | $48,247 | None |
| Administration of chemotherapy into vein, 1 hour or less | 178 | $41,228 | $100 |
| Injection, azacitidine, 1 mg | 15 | $39,204 | None |
| Injection, palonosetron hcl, 25 mcg | 112 | $33,460 | None |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 16 | $25,728 | None |
| Return visit (30+ min) | 162 | $19,302 | $78 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 213 | $16,872 | $10 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $16,075 | $158 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 156 | $13,463 | $23 |
| Blood test, comprehensive group of blood chemicals | 182 | $12,994 | $13 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 83 | $12,613 | $55 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 11 | $12,357 | None |
| Short return visit (20+ min) | 175 | $12,284 | $49 |
| New patient visit (60+ min) | 69 | $10,780 | $156 |
| Unclassified drugs | 36 | $10,392 | None |
| Cyclophosphamide, 100 mg | 13 | $8,832 | None |
| Injection, fosaprepitant, 1 mg | 31 | $8,745 | None |
| Injection of drug or substance under skin or into muscle | 178 | $8,259 | $19 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 18 | $6,693 | $1 |
| Injection, docetaxel, 1 mg | 11 | $6,019 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 66 | $5,665 | $46 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $5,467 | $79 |
| Infusion into a vein for hydration, 31-60 minutes | 44 | $4,567 | $43 |
| Injection, zoledronic acid, 1 mg | 19 | $4,458 | None |
| Administration of chemotherapy into vein, each additional hour | 64 | $3,769 | $21 |
| Irrigation of implanted venous access drug delivery device | 114 | $3,728 | $17 |
| Insertion of needle into vein for collection of blood sample | 215 | $3,466 | $3 |
| Administration of prolonged chemotherapy into vein | 16 | $3,307 | $103 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 35 | $2,925 | $50 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,923 | $56 |
| Infusion into a vein for hydration, each additional hour | 62 | $2,911 | $11 |
| Administration of additional new drug or substance into vein using push technique | 27 | $2,708 | $46 |
| Psa (prostate specific antigen) measurement, total | 20 | $2,702 | $24 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 20 | $2,442 | $28 |
| Injection of additional new drug or substance into vein | 80 | $2,335 | $17 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 20 | $2,231 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 91 | $2,218 | $15 |
| Carcinoembryonic antigen (cea) protein level | 17 | $1,816 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 54 | $1,318 | $16 |
| Magnesium level | 40 | $1,170 | $9 |
| Biopsy of bone marrow | 18 | $1,068 | $59 |
| Injection, carboplatin, 50 mg | 25 | $902 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $748 | $24 |
| Injection of drug or substance into vein | 12 | $632 | $39 |
| Ferritin (blood protein) level | 22 | $600 | $18 |
| Lactate dehydrogenase (enzyme) level | 50 | $569 | $5 |
| Blood test, thyroid stimulating hormone (tsh) | 11 | $538 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $526 | $14 |
| Injection, paclitaxel, 1 mg | 14 | $460 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $394 | $30 |
| Injection, dexamethasone sodium phosphate, 1 mg | 120 | $394 | None |
| Iron binding capacity | 18 | $303 | $12 |
| Injection, granisetron hydrochloride, 100 mcg | 18 | $296 | None |
| Injection, cisplatin, powder or solution, 10 mg | 11 | $249 | None |
| Iron level | 19 | $242 | $9 |
| Blood test, basic group of blood chemicals (calcium, total) | 12 | $169 | $11 |
| Phosphate level | 13 | $166 | $4 |
| Infusion, normal saline solution , 1000 cc | 50 | $160 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 18 | $124 | $7 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 22 | $88 | None |
| Uric acid level, blood | 12 | $84 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 99 | $76 | None |
| Injection, furosemide, up to 20 mg | 12 | $36 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $15 | None |
2014: 71 services
| Injection, pegfilgrastim, 6 mg | 65 | $272,406 | None |
| Injection, rituximab, 100 mg | 26 | $188,305 | None |
| Injection, denosumab, 1 mg | 66 | $161,490 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 64 | $152,321 | None |
| Injection, bortezomib, 0.1 mg | 22 | $141,982 | None |
| Injection, bevacizumab, 10 mg | 15 | $116,961 | None |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 13 | $72,633 | None |
| Long return visit (40+ min) | 267 | $63,184 | $105 |
| Injection, azacitidine, 1 mg | 12 | $49,649 | None |
| Injection, paclitaxel protein-bound particles, 1 mg | 14 | $44,430 | None |
| Administration of chemotherapy into vein, 1 hour or less | 186 | $43,899 | $97 |
| Injection, palonosetron hcl, 25 mcg | 129 | $39,140 | None |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 11 | $22,848 | None |
| Cyclophosphamide, 100 mg | 16 | $16,887 | None |
| Return visit (30+ min) | 138 | $16,581 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $16,550 | $155 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 220 | $16,141 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 178 | $16,099 | $22 |
| Short return visit (20+ min) | 176 | $13,381 | $51 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 78 | $12,505 | $54 |
| New patient visit (60+ min) | 76 | $11,504 | $151 |
| Blood test, comprehensive group of blood chemicals | 184 | $11,108 | $12 |
| Injection, zoledronic acid, 1 mg | 24 | $11,105 | None |
| Injection, fosaprepitant, 1 mg | 34 | $9,603 | None |
| Injection of drug or substance under skin or into muscle | 174 | $8,310 | $18 |
| Administration of additional new drug or substance into vein, 1 hour or less | 77 | $7,162 | $45 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $6,810 | $80 |
| Injection, docetaxel, 1 mg | 12 | $6,776 | None |
| Administration of chemotherapy into vein, each additional hour | 85 | $5,840 | $21 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 17 | $5,439 | $1 |
| Infusion into a vein for hydration, 31-60 minutes | 65 | $4,857 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $3,894 | $56 |
| Administration of prolonged chemotherapy into vein | 14 | $3,483 | $100 |
| Insertion of needle into vein for collection of blood sample | 216 | $3,436 | $3 |
| Irrigation of implanted venous access drug delivery device | 97 | $3,360 | $17 |
| Injection, oxaliplatin, 0.5 mg | 14 | $3,300 | None |
| Infusion into a vein for hydration, each additional hour | 74 | $2,964 | $11 |
| Injection, fondaparinux sodium, 0.5 mg | 13 | $2,898 | None |
| Administration of additional new drug or substance into vein using push technique | 22 | $2,687 | $45 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 31 | $2,504 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 100 | $2,486 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 24 | $2,450 | $49 |
| Magnesium level | 57 | $2,339 | $9 |
| Injection of additional new drug or substance into vein | 82 | $2,282 | $16 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 22 | $1,750 | None |
| Carcinoembryonic antigen (cea) protein level | 24 | $1,623 | $25 |
| Psa (prostate specific antigen) measurement, total | 13 | $1,623 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 70 | $1,606 | $15 |
| Injection, irinotecan, 20 mg | 14 | $1,204 | None |
| Collection of blood sample from central venous tube | 14 | $1,135 | $19 |
| Injection, carboplatin, 50 mg | 35 | $1,129 | None |
| Biopsy of bone marrow | 16 | $1,002 | $59 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $916 | $23 |
| Ferritin (blood protein) level | 35 | $875 | $18 |
| Lactate dehydrogenase (enzyme) level | 67 | $792 | $5 |
| Phosphate level | 47 | $776 | $4 |
| Injection of drug or substance into vein | 16 | $740 | $41 |
| Injection, paclitaxel, 30 mg | 24 | $632 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $485 | $30 |
| Iron binding capacity | 27 | $456 | $12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 132 | $452 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $427 | $13 |
| Iron level | 27 | $346 | $9 |
| Injection, granisetron hydrochloride, 100 mcg | 22 | $229 | None |
| Infusion, normal saline solution , 1000 cc | 64 | $139 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 109 | $101 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 14 | $96 | $7 |
| Uric acid level, blood | 17 | $95 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 19 | $78 | None |
| Unclassified drugs | 44 | $47 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $25 | None |
2013: 77 services
| Injection, pegfilgrastim, 6 mg | 71 | $228,974 | None |
| Injection, rituximab, 100 mg | 31 | $182,557 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 50 | $116,177 | None |
| Injection, azacitidine, 1 mg | 13 | $105,105 | None |
| Injection, denosumab, 1 mg | 37 | $101,024 | None |
| Injection, pemetrexed, not otherwise specified, 10 mg | 13 | $89,385 | None |
| Injection, bevacizumab, 10 mg | 12 | $76,219 | None |
| Injection, bortezomib, 0.1 mg | 11 | $70,156 | None |
| Long return visit (40+ min) | 282 | $69,899 | $104 |
| Unclassified drugs | 51 | $69,106 | None |
| Administration of chemotherapy into vein, 1 hour or less | 203 | $60,351 | $104 |
| Injection, palonosetron hcl, 25 mcg | 140 | $49,589 | None |
| Injection, paclitaxel protein-bound particles, 1 mg | 17 | $48,274 | None |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 16 | $30,476 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 188 | $20,956 | $23 |
| Injection, docetaxel, 1 mg | 17 | $18,707 | None |
| Injection, fosaprepitant, 1 mg | 47 | $15,866 | None |
| Return visit (30+ min) | 140 | $15,820 | $76 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 208 | $15,817 | $11 |
| Injection, zoledronic acid (zometa), 1 mg | 15 | $14,675 | None |
| Cyclophosphamide, 100 mg | 19 | $13,130 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $10,858 | $153 |
| Zoldedronic acid 1mg | 14 | $10,809 | $140 |
| Blood test, comprehensive group of blood chemicals | 175 | $10,422 | $12 |
| Injection, oxaliplatin, 0.5 mg | 14 | $10,331 | None |
| New patient visit (60+ min) | 65 | $9,834 | $151 |
| Short return visit (20+ min) | 144 | $9,688 | $51 |
| Administration of additional new drug or substance into vein, 1 hour or less | 81 | $8,285 | $52 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 45 | $7,287 | $55 |
| Administration of chemotherapy into vein, each additional hour | 92 | $7,127 | $23 |
| Injection of drug or substance under skin or into muscle | 157 | $6,340 | $19 |
| Administration of chemotherapy into vein using push technique | 14 | $5,542 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $5,527 | $78 |
| Administration of prolonged chemotherapy into vein | 18 | $4,148 | $104 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 25 | $3,492 | None |
| Injection of additional new drug or substance into vein | 104 | $3,351 | $16 |
| Insertion of needle into vein for collection of blood sample | 204 | $3,258 | $3 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $3,181 | $1 |
| Collection of blood sample from central venous tube | 19 | $3,141 | $20 |
| Administration of additional new drug or substance into vein using push technique | 30 | $3,105 | $46 |
| Irrigation of implanted venous access drug delivery device | 80 | $2,895 | $18 |
| Infusion into a vein for hydration, each additional hour | 46 | $2,555 | $11 |
| Magnesium level | 66 | $2,467 | $9 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 30 | $2,368 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 21 | $2,313 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,107 | $54 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 98 | $1,955 | $15 |
| Psa (prostate specific antigen) measurement, total | 15 | $1,767 | $25 |
| Infusion into a vein for hydration, 31-60 minutes | 25 | $1,411 | $42 |
| Injection, irinotecan, 20 mg | 14 | $1,382 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 62 | $1,361 | $14 |
| Injection, carboplatin, 50 mg | 35 | $1,318 | None |
| Biopsy of bone marrow | 21 | $1,302 | $57 |
| Carcinoembryonic antigen (cea) protein level | 14 | $1,233 | $26 |
| Phosphate level | 52 | $893 | $4 |
| Lactate dehydrogenase (enzyme) level | 68 | $883 | $5 |
| Injection, paclitaxel, 30 mg | 20 | $874 | None |
| Ferritin (blood protein) level | 27 | $719 | $18 |
| Injection of drug or substance into vein | 14 | $629 | $42 |
| Injection, doxorubicin hydrochloride, 10 mg | 12 | $553 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $528 | $29 |
| Injection, dexamethasone sodium phosphate, 1 mg | 141 | $449 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $430 | $24 |
| Injection, etoposide, 10 mg | 16 | $403 | None |
| Injection, granisetron hydrochloride, 100 mcg | 24 | $391 | None |
| Iron binding capacity | 27 | $379 | $12 |
| Iron level | 29 | $307 | $9 |
| Injection, cisplatin, powder or solution, 10 mg | 11 | $266 | None |
| Blood test, basic group of blood chemicals (calcium, total) | 14 | $240 | $11 |
| Uric acid level, blood | 17 | $158 | $3 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 21 | $150 | $7 |
| Injection, diphenhydramine hcl, up to 50 mg | 107 | $126 | None |
| Injection, fluorouracil, 500 mg | 14 | $92 | None |
| Infusion, normal saline solution , 1000 cc | 31 | $50 | None |
| Injection, furosemide, up to 20 mg | 12 | $42 | None |
| Injection, atropine sulfate, 0.01 mg | 11 | $25 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 22 | $22 | None |
Medicaid work
$219 in 2024
Medicaid paid $219 for 37 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| COMPREHENSIVE METABOLIC PANEL | 17 | $138 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 20 | $81 |
| 2024 | 37 | 2 | 13 | $219 |
| 2023 | 174 | 4 | 19 | $2,631 |
| 2022 | 13 | 1 | 13 | $722 |
See the largest Medicaid services in earlier years
2023
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 15 | $1,509 |
| Long return visit (40+ min) | 16 | $427 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 108 | $417 |
| COMPREHENSIVE METABOLIC PANEL | 35 | $278 |
2022
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 13 | $722 |
Drugs they prescribed that Part D paid
$1,006,016
Pharmacies billed $1,006,016 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (16 of 737) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
647 generic and 90 brand-name prescriptions · $1,006,016 in drug cost · 29 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nubeqa | 13 | $168,884 | $12,991 |
| Lenalidomide | 12 | $159,990 | $13,333 |
| Eliquis | 11 | $7,004 | $637 |
| Anastrozole | 160 | $3,443 | $22 |
| Tamoxifen Citrate | 30 | $646 | $22 |
See all 17 drugs
| Nubeqa | 13 | $168,884 | $12,991 |
| Lenalidomide | 12 | $159,990 | $13,333 |
| Eliquis | 11 | $7,004 | $637 |
| Anastrozole | 160 | $3,443 | $22 |
| Tamoxifen Citrate | 30 | $646 | $22 |
| Dexamethasone | 55 | $624 | $11 |
| Acyclovir | 43 | $537 | $12 |
| Hydroxyurea | 19 | $471 | $25 |
| Letrozole | 30 | $420 | $14 |
| Prochlorperazine Maleate | 26 | $337 | $13 |
| Ondansetron | 22 | $330 | $15 |
| Gabapentin | 15 | $327 | $22 |
| Levothyroxine | 17 | $185 | $11 |
| Duloxetine | 13 | $117 | $9 |
| Prednisone | 26 | $106 | $4 |
| Anagrelide | 12 | $79 | $7 |
| Pantoprazole | 11 | $79 | $7 |
Year by year
| 2024 | 737 | 224 | 2% (16) | 12% | $1,006,016 |
| 2023 | 1,399 | 263 | 2% (32) | None | $956,460 |
| 2022 | 1,465 | 263 | 3% (45) | None | $745,665 |
| 2021 | 1,184 | 230 | 2% (23) | 8% | $572,343 |
| 2020 | 1,161 | 211 | 3% (31) | 7% | $488,259 |
| 2019 | 949 | 216 | 6% (59) | 9% | $363,748 |
| 2018 | 907 | 225 | 9% (83) | None | $630,543 |
| 2017 | 1,055 | 218 | 8% (85) | None | $579,559 |
| 2016 | 1,191 | 233 | 8% (97) | 16% | $1,001,464 |
| 2015 | 1,103 | 217 | 7% (76) | None | $1,105,108 |
| 2014 | 1,043 | 226 | 9% (94) | None | $774,065 |
| 2013 | 1,158 | 207 | 11% (123) | 18% | $1,001,917 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Everolimus | 12 | $136,874 | $11,406 |
| Abiraterone Acetate | 24 | $61,327 | $2,555 |
| Xarelto | 25 | $20,244 | $810 |
| Eliquis | 29 | $16,665 | $575 |
| Anastrozole | 262 | $5,677 | $22 |
| Exemestane | 23 | $5,296 | $230 |
| Enoxaparin | 14 | $3,029 | $216 |
| Tamoxifen Citrate | 53 | $2,020 | $38 |
| Gabapentin | 63 | $1,574 | $25 |
| Dexamethasone | 112 | $1,325 | $12 |
| Letrozole | 47 | $994 | $21 |
| Hydroxyurea | 47 | $888 | $19 |
| Acyclovir | 61 | $657 | $11 |
| Prednisone | 94 | $629 | $7 |
| Prochlorperazine Maleate | 50 | $544 | $11 |
| Levothyroxine | 46 | $500 | $11 |
| Duloxetine | 20 | $407 | $20 |
| Oxycodone | 15 | $379 | $25 |
| Ondansetron Odt | 22 | $347 | $16 |
| Anagrelide | 24 | $260 | $11 |
| Omeprazole | 18 | $202 | $11 |
| Pantoprazole | 19 | $201 | $11 |
| Potassium Chloride | 14 | $169 | $12 |
| Celecoxib | 11 | $148 | $13 |
| Alendronate | 18 | $94 | $5 |
| Levofloxacin | 12 | $67 | $6 |
| Sulfamethoxazole-Trimethoprim | 20 | $67 | $3 |
| Furosemide | 16 | $61 | $4 |
| Folic Acid | 13 | $20 | $2 |
2022: 27 drugs
| Ibrance | 11 | $149,874 | $13,625 |
| Abiraterone Acetate | 14 | $47,539 | $3,396 |
| Xarelto | 19 | $18,170 | $956 |
| Eliquis | 28 | $17,043 | $609 |
| Anastrozole | 257 | $7,327 | $29 |
| Exemestane | 17 | $7,256 | $427 |
| Dexamethasone | 143 | $2,131 | $15 |
| Tamoxifen Citrate | 48 | $1,714 | $36 |
| Letrozole | 66 | $1,199 | $18 |
| Gabapentin | 55 | $954 | $17 |
| Doxycycline Hyclate | 14 | $849 | $61 |
| Hydroxyurea | 58 | $799 | $14 |
| Acyclovir | 64 | $699 | $11 |
| Prednisone | 132 | $659 | $5 |
| Bicalutamide | 15 | $641 | $43 |
| Anagrelide | 12 | $596 | $50 |
| Ondansetron Odt | 22 | $490 | $22 |
| Prochlorperazine Maleate | 69 | $449 | $7 |
| Oxycodone | 16 | $325 | $20 |
| Pantoprazole | 24 | $275 | $11 |
| Ondansetron | 17 | $246 | $14 |
| Levothyroxine | 26 | $204 | $8 |
| Finasteride | 12 | $183 | $15 |
| Potassium Chloride | 12 | $152 | $13 |
| Omeprazole | 18 | $125 | $7 |
| Alendronate | 25 | $64 | $3 |
| Furosemide | 11 | $57 | $5 |
2021: 25 drugs
| Calquence | 11 | $155,559 | $14,142 |
| Xarelto | 21 | $14,276 | $680 |
| Eliquis | 18 | $10,328 | $574 |
| Anastrozole | 253 | $7,458 | $29 |
| Exemestane | 17 | $4,837 | $285 |
| Enoxaparin | 13 | $2,520 | $194 |
| Tamoxifen Citrate | 51 | $1,710 | $34 |
| Dexamethasone | 124 | $1,360 | $11 |
| Hydroxyurea | 62 | $1,138 | $18 |
| Gabapentin | 41 | $929 | $23 |
| Potassium Chloride | 22 | $796 | $36 |
| Letrozole | 32 | $627 | $20 |
| Bicalutamide | 16 | $582 | $36 |
| Prochlorperazine Maleate | 65 | $499 | $8 |
| Sucralfate | 14 | $470 | $34 |
| Acyclovir | 36 | $297 | $8 |
| Cephalexin | 11 | $283 | $26 |
| Ondansetron Odt | 20 | $280 | $14 |
| Ondansetron | 15 | $274 | $18 |
| Pantoprazole | 13 | $266 | $20 |
| Omeprazole | 29 | $263 | $9 |
| Prednisone | 61 | $206 | $3 |
| Levothyroxine | 17 | $53 | $3 |
| Cyclobenzaprine | 11 | $45 | $4 |
| Alendronate | 20 | $24 | $1 |
2020: 20 drugs
| Xarelto | 20 | $13,356 | $668 |
| Enoxaparin | 12 | $6,423 | $535 |
| Exemestane | 17 | $5,354 | $315 |
| Anagrelide | 12 | $5,198 | $433 |
| Anastrozole | 262 | $4,708 | $18 |
| Potassium Chloride | 28 | $3,609 | $129 |
| Dexamethasone | 196 | $2,523 | $13 |
| Tamoxifen Citrate | 44 | $1,718 | $39 |
| Hydroxyurea | 33 | $850 | $26 |
| Letrozole | 20 | $776 | $39 |
| Prochlorperazine Maleate | 65 | $590 | $9 |
| Prednisone | 71 | $350 | $5 |
| Gabapentin | 27 | $325 | $12 |
| Ondansetron | 21 | $297 | $14 |
| Acyclovir | 49 | $267 | $5 |
| Ondansetron Odt | 12 | $206 | $17 |
| Finasteride | 12 | $184 | $15 |
| Cephalexin | 13 | $77 | $6 |
| Zolpidem | 12 | $50 | $4 |
| Levofloxacin | 15 | $41 | $3 |
2019: 19 drugs
| Exemestane | 26 | $7,284 | $280 |
| Potassium Chloride | 29 | $6,097 | $210 |
| Enoxaparin | 12 | $5,939 | $495 |
| Anastrozole | 197 | $4,704 | $24 |
| Tamoxifen Citrate | 29 | $1,800 | $62 |
| Hydroxyurea | 36 | $1,101 | $31 |
| Dexamethasone | 82 | $942 | $11 |
| Letrozole | 16 | $935 | $58 |
| Hydrocodone-Acetaminophen | 14 | $717 | $51 |
| Bicalutamide | 11 | $524 | $48 |
| Gabapentin | 33 | $394 | $12 |
| Prochlorperazine Maleate | 37 | $314 | $8 |
| Ondansetron Odt | 11 | $286 | $26 |
| Acyclovir | 29 | $229 | $8 |
| Prednisone | 56 | $203 | $4 |
| Finasteride | 12 | $188 | $16 |
| Ondansetron | 14 | $157 | $11 |
| Zolpidem | 19 | $58 | $3 |
| Jantoven | 22 | $25 | $1 |
2018: 19 drugs
| Enoxaparin | 13 | $17,668 | $1,359 |
| Exemestane | 14 | $6,524 | $466 |
| Potassium Chloride | 29 | $5,759 | $199 |
| Anastrozole | 202 | $3,711 | $18 |
| Tamoxifen Citrate | 62 | $2,172 | $35 |
| Hydroxyurea | 41 | $1,280 | $31 |
| Oxycodone | 27 | $785 | $29 |
| Hydrocodone-Acetaminophen | 18 | $709 | $39 |
| Dexamethasone | 64 | $567 | $9 |
| Letrozole | 11 | $344 | $31 |
| Prednisone | 53 | $338 | $6 |
| Prochlorperazine Maleate | 35 | $324 | $9 |
| Ondansetron | 13 | $305 | $23 |
| Citalopram Hbr | 15 | $253 | $17 |
| Acyclovir | 21 | $177 | $8 |
| Gabapentin | 15 | $147 | $10 |
| Sulfamethoxazole-Trimethoprim | 19 | $133 | $7 |
| Ondansetron Odt | 13 | $107 | $8 |
| Levofloxacin | 12 | $67 | $6 |
2017: 21 drugs
| Revlimid | 12 | $160,346 | $13,362 |
| Pradaxa | 16 | $5,952 | $372 |
| Exemestane | 12 | $5,340 | $445 |
| Potassium Chloride | 32 | $5,050 | $158 |
| Anastrozole | 230 | $3,299 | $14 |
| Tamoxifen Citrate | 82 | $2,527 | $31 |
| Fentanyl | 11 | $1,536 | $140 |
| Hydroxyurea | 38 | $1,311 | $35 |
| Oxycodone | 26 | $795 | $31 |
| Dexamethasone | 108 | $661 | $6 |
| Prochlorperazine Maleate | 61 | $451 | $7 |
| Hydrocodone-Acetaminophen | 11 | $406 | $37 |
| Ondansetron | 14 | $378 | $27 |
| Ondansetron Odt | 19 | $325 | $17 |
| Zolpidem | 28 | $238 | $8 |
| Prednisone | 34 | $219 | $6 |
| Letrozole | 13 | $208 | $16 |
| Acyclovir | 29 | $197 | $7 |
| Omeprazole | 19 | $128 | $7 |
| Levofloxacin | 13 | $106 | $8 |
| Lorazepam | 14 | $63 | $5 |
2016: 24 drugs
| Revlimid | 12 | $136,233 | $11,353 |
| Xtandi | 15 | $134,786 | $8,986 |
| Imbruvica | 11 | $111,928 | $10,175 |
| Zytiga | 11 | $93,929 | $8,539 |
| Anastrozole | 257 | $3,761 | $15 |
| Tamoxifen Citrate | 69 | $2,033 | $29 |
| Hydroxyurea | 43 | $1,031 | $24 |
| Hydrocodone-Acetaminophen | 18 | $683 | $38 |
| Oxycodone | 19 | $633 | $33 |
| Prochlorperazine Maleate | 70 | $476 | $7 |
| Letrozole | 27 | $434 | $16 |
| Dexamethasone | 88 | $357 | $4 |
| Klor-Con M20 | 18 | $350 | $19 |
| Hydromorphone | 12 | $298 | $25 |
| Zolpidem | 21 | $280 | $13 |
| Diphenoxylate-Atropine | 12 | $273 | $23 |
| Warfarin | 13 | $273 | $21 |
| Acyclovir | 28 | $260 | $9 |
| Omeprazole | 33 | $244 | $7 |
| Prednisone | 28 | $224 | $8 |
| Lorazepam | 23 | $167 | $7 |
| Alendronate | 11 | $135 | $12 |
| Pantoprazole | 23 | $134 | $6 |
| Potassium Chloride | 19 | $81 | $4 |
2015: 20 drugs
| Revlimid | 36 | $356,222 | $9,895 |
| Tasigna | 13 | $210,148 | $16,165 |
| Promacta | 11 | $17,030 | $1,548 |
| Anastrozole | 212 | $3,678 | $17 |
| Tamoxifen Citrate | 87 | $2,943 | $34 |
| Methotrexate | 11 | $1,916 | $174 |
| Hydroxyurea | 43 | $1,420 | $33 |
| Hydromorphone | 12 | $610 | $51 |
| Oxycodone | 17 | $592 | $35 |
| Dexamethasone | 97 | $468 | $5 |
| Hydrocodone-Acetaminophen | 14 | $424 | $30 |
| Zolpidem | 22 | $279 | $13 |
| Acyclovir | 42 | $274 | $7 |
| Prochlorperazine Maleate | 69 | $269 | $4 |
| Potassium Chloride | 12 | $259 | $22 |
| Letrozole | 12 | $226 | $19 |
| Levofloxacin | 15 | $214 | $14 |
| Omeprazole | 29 | $191 | $7 |
| Alendronate | 18 | $178 | $10 |
| Pantoprazole | 16 | $68 | $4 |
2014: 22 drugs
| Revlimid | 26 | $258,474 | $9,941 |
| Zytiga | 15 | $104,891 | $6,993 |
| Tarceva | 12 | $72,767 | $6,064 |
| Anastrozole | 205 | $5,444 | $27 |
| Carafate | 13 | $2,412 | $186 |
| Tamoxifen Citrate | 67 | $1,950 | $29 |
| Hydroxyurea | 28 | $1,023 | $37 |
| Oxycodone | 27 | $972 | $36 |
| Methotrexate | 13 | $911 | $70 |
| Oxycodone-Acetaminophen | 15 | $520 | $35 |
| Dexamethasone | 90 | $497 | $6 |
| Acyclovir | 37 | $298 | $8 |
| Hydrocodone-Acetaminophen | 15 | $287 | $19 |
| Prednisone | 40 | $284 | $7 |
| Prochlorperazine Maleate | 55 | $267 | $5 |
| Potassium Chloride | 14 | $223 | $16 |
| Alendronate | 18 | $199 | $11 |
| Zolpidem | 18 | $154 | $9 |
| Levofloxacin | 16 | $153 | $10 |
| Lorazepam | 16 | $100 | $6 |
| Ibuprofen | 19 | $91 | $5 |
| Pantoprazole | 12 | $87 | $7 |
2013: 26 drugs
| Revlimid | 46 | $466,698 | $10,146 |
| Zytiga | 15 | $74,263 | $4,951 |
| Oxycontin | 17 | $8,367 | $492 |
| Anastrozole | 206 | $7,367 | $36 |
| Fentanyl | 17 | $3,564 | $210 |
| Oxycodone | 30 | $1,723 | $57 |
| Escitalopram | 32 | $1,384 | $43 |
| Tamoxifen Citrate | 56 | $1,244 | $22 |
| Letrozole | 22 | $1,093 | $50 |
| Methotrexate | 13 | $1,074 | $83 |
| Hydroxyurea | 21 | $892 | $42 |
| Megestrol Acetate | 17 | $752 | $44 |
| Hydromorphone | 14 | $743 | $53 |
| Levofloxacin | 27 | $352 | $13 |
| Dexamethasone | 73 | $332 | $5 |
| Acyclovir | 25 | $311 | $12 |
| Prochlorperazine Maleate | 64 | $309 | $5 |
| Oxycodone-Acetaminophen | 15 | $306 | $20 |
| Prednisone | 51 | $224 | $4 |
| Alendronate | 14 | $199 | $14 |
| Ondansetron | 12 | $189 | $16 |
| Pantoprazole | 11 | $178 | $16 |
| Lorazepam | 19 | $120 | $6 |
| Fluconazole | 11 | $94 | $9 |
| Cephalexin | 12 | $93 | $8 |
| Zolpidem | 11 | $65 | $6 |
Money from drug and device companies
$13 in 2024
| 2024 | 1 | 1 | None | $13 |
| 2023 | 3 | 3 | None | $38 |
| 2022 | 9 | 14 | None | $269 |
| 2021 | 18 | 30 | None | $407 |
| 2020 | 15 | 24 | None | $575 |
| 2019 | 11 | 59 | None | $596 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Fresenius Kabi USA | Stimufend | $13 | 1 payment
|
See the published payment
| Fresenius Kabi USA | Meals · 2024-01-18 | Stimufend | $13 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $38
| Celgene | Reblozyl | $15 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $13 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $9 | 1 payment
|
2022: $269
| E.R. Squibb & Sons L.L.C. | Opdivo | $134 | 5 payments
|
| Agios Pharmaceuticals | Pyrukynd | $25 | 1 payment
|
| Daiichi Sankyo | Enhertu | $24 | 2 payments
|
| Abbvie | Venclexta | $17 | 1 payment
|
| Array Biopharma | Braftovi | $16 | 1 payment
|
| BeiGene USA | Brukinsa | $14 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $14 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $12 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $12 | 1 payment
|
2021: $407
| Janssen Biotech | Erleada | $67 | 6 payments
|
| Seagen | Tukysa | $61 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $58 | 4 payments
|
| Global Blood Therapeutics | Oxbryta | $40 | 3 payments
|
| AbbVie | Venclexta | $27 | 2 payments
|
| Daiichi Sankyo | Injectafer | $13 | 1 payment
|
| Foundation Medicine | Foundationone | $12 | 1 payment
|
| TerSera Therapeutics | Zoladex | $12 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $12 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $12 | 1 payment
|
| EMD Serono | None | $12 | 1 payment
|
| Acrotech Biopharma | Zevalin | $12 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $12 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $12 | 1 payment
|
| Genzyme | Cablivi | $12 | 1 payment
|
| BeiGene USA | Brukinsa | $11 | 1 payment
|
| Janssen Scientific Affairs | Darzalex | $11 | 1 payment
|
2020: $575
| Epizyme | Tazverik | $147 | 2 payments
|
| Janssen Biotech | Erleada | $124 | 4 payments
|
| Astellas Pharma US | None | $85 | 1 payment
|
| AbbVie | Venclexta | $36 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $29 | 2 payments
|
| GlaxoSmithKline | Zejula | $23 | 1 payment
|
| Genentech USA | Perjeta | $22 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $17 | 2 payments
|
| Octapharma USA | Octagam Immune Globulin (Human) | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $14 | 1 payment
|
| Genzyme | Elitek | $12 | 1 payment
|
| Global Blood Therapeutics | Oxbryta | $12 | 1 payment
|
| Janssen Scientific Affairs | Darzalex | $12 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $12 | 1 payment
|
| Aurobindo Pharma USA | Marqibo | $11 | 1 payment
|
2019: $596
| Pfizer | Xtandi | $132 | 23 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $110 | 15 payments
|
| Sun Pharmaceutical Industries | Yonsa | $86 | 1 payment
|
| Janssen Biotech | Erleada | $76 | 8 payments
|
| Puma Biotechnology | Nerlynx | $69 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $38 | 5 payments
|
| Lexicon Pharmaceuticals | Xermelo | $25 | 2 payments
|
| Jazz Pharmaceuticals | Vyxeos | $20 | 1 payment
|
| Janssen Scientific Affairs | Darzalex | $19 | 1 payment
|
| Celgene | Inrebic | $11 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $11 | 1 payment
|
Professional record
- NPI
- 1871592154
- Licence
- PA MD070951L
- Group
- Monterey Bay Oncology A Medical Corporation · Dignity Health Medical Foundation
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 15400 National Ave Ste 201, Los Gatos, CA, 95032
- NPI first listed
- 2005-07-19
- NPI last updated
- 2026-05-14
- NPI record certified
- 2026-05-14
This is when the NPI record was last certified, not a medical board exam.